Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data ...
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...
1d
Tuesday reported encouraging results from its Phase 2 study of MariTide in people with obesity. Results from the 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback